Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Moderate to Severe Plaque Psoriasis After IL-17 or IL-23 Failure
NCT06336343Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of bimekizumab in plaque psoriasis, sponsored by Icahn School of Medicine at Mount Sinai. Started Jun 2024; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06336343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336343.